Healthcare >> CEO Interviews >> April 28, 2003
MICHAEL J. ABRAMS is President, Chief Executive Officer and
Director of Anormed. Dr. Abrams has been active in the research,
discovery and development of pharmaceuticals for over 20 years.
He is an inventor on the patents that led to the development of
the DuPont technetium-99m heart imaging agent, Cardiolite' and is
a co-inventor on several products currently in clinical trials.
In 1991, Dr. Abrams was promoted to Manager, Biomedical Research,
worldwide for Johnson Matthey Plc, and in June 1996 established
the Canadian venture-backed financing of AnorMED Inc. He is a
named inventor on 15 patents and has authored over 60 scientific
articles. He received his PhD in Chemistry from the Massachusetts
Institute of Technology. Dr. Abrams also serves as a Director on
the Boards of an early stage technology company, a technology
investment fund, and the British Columbia Biotechnology
Association. He is also an adjunct Professor at the University of
British Columbia. Profile
AnorMED since you last spoke to us six months ago?
Dr. Abrams: AnorMED is a company that discovers and develops
small molecule
